| Literature DB >> 27188339 |
Faysal A Yafi1, Lawrence Jenkins2, Maarten Albersen3, Giovanni Corona4, Andrea M Isidori5, Shari Goldfarb6, Mario Maggi7, Christian J Nelson6, Sharon Parish8, Andrea Salonia9, Ronny Tan10, John P Mulhall2, Wayne J G Hellstrom1.
Abstract
Erectile dysfunction is a multidimensional but common male sexual dysfunction that involves an alteration in any of the components of the erectile response, including organic, relational and psychological. Roles for nonendocrine (neurogenic, vasculogenic and iatrogenic) and endocrine pathways have been proposed. Owing to its strong association with metabolic syndrome and cardiovascular disease, cardiac assessment may be warranted in men with symptoms of erectile dysfunction. Minimally invasive interventions to relieve the symptoms of erectile dysfunction include lifestyle modifications, oral drugs, injected vasodilator agents and vacuum erection devices. Surgical therapies are reserved for the subset of patients who have contraindications to these nonsurgical interventions, those who experience adverse effects from (or are refractory to) medical therapy and those who also have penile fibrosis or penile vascular insufficiency. Erectile dysfunction can have deleterious effects on a man's quality of life; most patients have symptoms of depression and anxiety related to sexual performance. These symptoms, in turn, affect his partner's sexual experience and the couple's quality of life. This Primer highlights numerous aspects of erectile dysfunction, summarizes new treatment targets and ongoing preclinical studies that evaluate new pharmacotherapies, and covers the topic of regenerative medicine, which represents the future of sexual medicine.Entities:
Mesh:
Year: 2016 PMID: 27188339 PMCID: PMC5027992 DOI: 10.1038/nrdp.2016.3
Source DB: PubMed Journal: Nat Rev Dis Primers ISSN: 2056-676X Impact factor: 52.329